Platinum-Based Drugs in Cancer Therapy

  • Lloyd R. Kelland
  • Nicholas P. Farrell

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Platinum Chemistry

    1. Front Matter
      Pages 1-1
    2. Susan J. Berners-Price, Trevor G. Appleton
      Pages 3-35
    3. Marc Leng, Annie Schwartz, Marie-Josephe Giraud-Panis
      Pages 63-85
  3. Platinum Biochemistry

    1. Front Matter
      Pages 87-87
    2. Paul A. Andrews
      Pages 89-113
    3. Robert Brown
      Pages 115-128
    4. Stephen G. Chaney, Alexandra Vaisman
      Pages 129-148
    5. Daniel Fink, Stephen B. Howell
      Pages 149-167
  4. Clinical Antitumor Activity and Toxicology of Platinum Drugs

    1. Front Matter
      Pages 169-169
    2. Martin S. Highley, A. Hilary Calvert
      Pages 171-194
    3. Michelle Vaughan, Francisco Sapunar, Martin Gore
      Pages 195-230
    4. Peter J. O’Dwyer, James P. Stevenson, Steven W. Johnson
      Pages 231-249
    5. Diana L. Clark, Paul A. Andrews, D. D. Smith, Joseph J. DeGeorge, Robert L. Justice, Julie G. Beitz
      Pages 277-296
  5. New Platinum Drugs of the Future

    1. Front Matter
      Pages 297-297
    2. Lloyd R. Kelland
      Pages 299-319
  6. Back Matter
    Pages 339-341

About this book


In Platinum-Based Drugs in Cancer Therapy, leading international experts comprehensively review all aspects of platinum anticancer drugs and their current use in treatment, as well as examining their future therapeutic prospects. Writing from a variety of disciplines, these authorities discuss the chemistry of cisplatin in aqueous solution, the molecular interaction of platinum drugs with DNA, and such exciting new areas as DNA mismatch repair, replicative bypass, apoptosis, and the transport of platinum drugs into tumor cells. The antitumor activity and toxicology of platinum-based drugs is also addressed in a thorough discussion of the clinical experience with cisplatin and carboplatin, including their promising recent combinations with taxanes and oxaliplatin. The emergent platinum drugs of the future-orally active agents, the sterically hindered ZD0473, and the polynuclear charged platinum BBR3464-are also fully considered.
Timely and interdisciplinary, Platinum-Based Drugs in Cancer Therapy offers cancer therapeutics specialists an illuminating survey of every aspect of platinum drugs from mechanisms of action to toxicology, tumor resistance, and new analogs. This important book captures the essence of the fresh clinical possibilities now strongly emerging thirty years after cisplatin's discovery.


DNA apoptosis biochemistry cancer cancer therapy chemistry ovarian cancer research resistance toxicology tumor

Editors and affiliations

  • Lloyd R. Kelland
    • 1
  • Nicholas P. Farrell
    • 2
  1. 1.CRC Centre for Cancer TherapeuticsThe Institute of Cancer ResearchUK
  2. 2.Department of ChemistryVirginia Commonwealth UniversityUSA

Bibliographic information